A Study to Evaluate the Safety of Recombinant Herpes Zoster Vaccine for Healthy Individuals

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

Hubei Provincial Center for Disease Control and Prevention, Wuhan, Hubei